{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T08:19:10Z","timestamp":1787818750482,"version":"build-2784847793"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"DOI":"10.1007\/s00115-026-02004-y","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T07:54:25Z","timestamp":1787817265000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Die S3-Leitlinie Demenzen (\u201eliving guideline\u201c)\u00a0\u2013 Was gibt es Neues?","The S3 guideline on dementia (living guideline)\u2014What is new?"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1067-2102","authenticated-orcid":false,"given":"Frank","family":"Jessen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Bohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Dodel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"2004_CR1","unstructured":"DGPPN & DGN (2026) S3-Leitlinie Demenzen. AWMF-Registernummer 038-013, Version 6.1. AWMF-Leitlinienregister."},{"issue":"7","key":"2004_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2026.100598","volume":"13","author":"KS Frederiksen","year":"2026","unstructured":"Frederiksen\u00a0KS, Boada\u00a0M, Fr\u00f6lich\u00a0L et\u00a0al (2026) Class-level aggregation obscures clinically relevant heterogeneity in anti-amyloid antibody trials: comments on a\u00a0Cochrane review by individual members of the EADC. J\u00a0Prev Alzheimers Dis 13(7):100598","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"2004_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-024-02801-2","volume":"148","author":"T Freiburghaus","year":"2024","unstructured":"Freiburghaus\u00a0T, Pawlik\u00a0D, Oliveira Hauer\u00a0K et\u00a0al (2024) Association of in vivo retention of [18f] flortaucipir pet with tau neuropathology in corresponding brain regions. Acta Neuropathie 148(1):44","journal-title":"Acta Neuropathie"},{"key":"2004_CR4","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) (2025) Lecanemab (fr\u00fche Alzheimer-Krankheit) \u2013 Nutzenbewertung gem\u00e4\u00df \u00a7\u00a035a\u00a0SGB\u00a0V. Dossierbewertung (Projekt A25-111)."},{"key":"2004_CR5","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) (2026) Donanemab (fr\u00fche Alzheimer-Krankheit) \u2013 Nutzenbewertung gem\u00e4\u00df \u00a7\u00a035a\u00a0SGB\u00a0V. Dossierbewertung (Projekt A25-134)."},{"issue":"2","key":"2004_CR6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.59170","volume":"8","author":"E Matt","year":"2025","unstructured":"Matt\u00a0E, Mitterwallner\u00a0M, Radjenovic\u00a0S et\u00a0al (2025) Ultrasound Neuromodulation With Transcranial Pulse Stimulation in Alzheimer Disease: A Randomized Clinical Trial. JAMA Netw Open 8(2):e2459170","journal-title":"JAMA Netw Open"},{"issue":"4","key":"2004_CR7","volume":"4","author":"F Nonino","year":"2026","unstructured":"Nonino\u00a0F, Minozzi\u00a0S, Sambati\u00a0L et\u00a0al (2026) Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer\u2019s disease. Cochrane Database Syst Rev 4(4):CD016297","journal-title":"Cochrane Database Syst Rev"},{"key":"2004_CR8","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.zefq.2025.05.003","volume":"196","author":"M Nothacker","year":"2025","unstructured":"Nothacker\u00a0M, Dreger\u00a0J, Kopp\u00a0I, Bl\u00f6dt\u00a0S (2025) \u201eLiving guideline recommendations\u201c - more important than ever?! Successes and challenges of \u201eliving guidelines\u201c: A\u00a0systematic evaluation. Z Evid Fortbild Qual Gesundhwes 196:72\u201381","journal-title":"Z Evid Fortbild Qual Gesundhwes"},{"issue":"1","key":"2004_CR9","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","volume":"21","author":"CE Teunissen","year":"2022","unstructured":"Teunissen\u00a0CE, Verberk\u00a0IMW, Thijssen\u00a0EH et\u00a0al (2022) Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation. Lancet Neurol 21(1):66\u201377","journal-title":"Lancet Neurol"},{"issue":"1","key":"2004_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14202","volume":"21","author":"DA Wolk","year":"2025","unstructured":"Wolk\u00a0DA, Nelson\u00a0PT, Apostolova\u00a0L et\u00a0al (2025) Clinical criteria for limbic-predominant age-related TDP-43 encephalopathy. Alzheimers Dement 21(1):e14202","journal-title":"Alzheimers Dement"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-026-02004-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-026-02004-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-026-02004-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T07:54:26Z","timestamp":1787817266000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-026-02004-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":10,"alternative-id":["2004"],"URL":"https:\/\/doi.org\/10.1007\/s00115-026-02004-y","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"assertion":[{"value":"15 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"F.\u00a0Jessen: Forschungsf\u00f6rderung von: Roche; Honorare f\u00fcr Beratung und Vortr\u00e4ge von: Abbvie, AC immune, Biogen, BMS, Eli Lilly, Eisai, GE Healthcare, Grifols, Johnson & Johnson, Novo Nordisk, Priavoid, Roche, Sanofi. R.\u00a0Dodel: Forschungsf\u00f6rderung von: Lilly, Roche; Honorare f\u00fcr Beratung von: f\u00fcr Lilly, Roche, Eisai, Novo Nordisk; Honorar f\u00fcr Vortr\u00e4ge von: AbbVie, Bayer Vital, Lilly, Eisai, Schwabe, Roche; Publikationsverg\u00fctungen von: Kohlhammer, Elsevier, Thieme; Erfinder auf Patenten der Philipps-Universit\u00e4t Marburg zur Immunisierung bei neurodegenerativen Erkrankungen. L.\u00a0Bohr gibt an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Ethics"}}]}}